← Back to Search

Overdose Prevention Intervention for Drug Overdose (Oasis Trial)

N/A
Recruiting
Led By Carl Latkin, PhD
Research Sponsored by Johns Hopkins Bloomberg School of Public Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Oasis Trial Summary

This trial is testing whether a targeted, peer-driven intervention can reduce HIV and HCV transmission, as well as overdose risk behaviors, among people who inject drugs.

Who is the study for?
This trial is for current opioid users who have used within the last two weeks. It's aimed at people who inject drugs and are at risk of HIV, hepatitis C, or drug overdose. Participants must be able to engage in the study without mental or physical health issues interfering.Check my eligibility
What is being tested?
The study tests a new peer-driven intervention designed to reduce the risks of HIV, hepatitis C virus transmission, and overdoses among those who inject drugs. It's a pilot program focusing on injection settings.See study design
What are the potential side effects?
Since this is an educational and behavioral intervention rather than a medication-based one, traditional side effects like you'd see with drugs aren't expected. However, participants may experience stress or emotional discomfort.

Oasis Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HIV/HCV prevention
Overdose prevention
Secondary outcome measures
Overdose behaviors
Overdose behaviors 2

Oasis Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
behavioral training with 6 sessions
Group II: comparisonActive Control1 Intervention
Attention control

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,455 Previous Clinical Trials
2,596,695 Total Patients Enrolled
Johns Hopkins Bloomberg School of Public HealthLead Sponsor
410 Previous Clinical Trials
2,116,665 Total Patients Enrolled
Carl Latkin, PhDPrincipal InvestigatorJohns Hopkins Bloomberg School of Public Health
5 Previous Clinical Trials
4,042 Total Patients Enrolled

Media Library

HIV, HCV and overdose prevention Clinical Trial Eligibility Overview. Trial Name: NCT05320835 — N/A
Human Immunodeficiency Virus Infection Research Study Groups: Experimental, comparison
Human Immunodeficiency Virus Infection Clinical Trial 2023: HIV, HCV and overdose prevention Highlights & Side Effects. Trial Name: NCT05320835 — N/A
HIV, HCV and overdose prevention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05320835 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participation in this clinical trial?

"Affirmative. The details on clinicaltrials.gov confirm that the trial, initially posted April 30th 2022, is presently enrolling participants. About 285 individuals must be recruited from a single medical centre."

Answered by AI

How many participants are eligible to take part in this clinical research?

"Affirmative. Per information accessible on clinicaltrials.gov, this study is currently looking for participants to enrol. The trial was first posted April 30th 2022 and most recently updated September 7th 2022; the research seeks 285 volunteers from a single location."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
How old are they?
65+
What site did they apply to?
Lighthouse Studies at Peer Point
What portion of applicants met pre-screening criteria?
Did not meet criteria
~133 spots leftby Dec 2025